GlassScriptPhysician profile
Todd Mcmurdie
NPI 1972621258
$4,392.82
in general payments reported to CMS, 2019-2025
27 companies · $777 in 2025
The $777 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,244 · 2022: $1,325 · 2023: $576 · 2024: $470 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,184.72 | 2021-2024 | Senza |
| Boston Scientific Corporation | $753.99 | 2021-2025 | General - Vascular Intervention, Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Spinal Simplicity, LLC | $486.07 | 2022-2025 | Ha Minuteman G3-R |
| Globus Medical, INC. | $333.57 | 2025 | Senza, Omnia |
| Nalu Medical, INC. | $218.71 | 2023-2024 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $199.88 | 2022-2024 | Mild Device Kit |
| Curonix LLC | $165.31 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $155.26 | 2021-2024 | Proclaim |
| Abbvie INC. | $137.67 | 2021-2022 | |
| Amgen INC. | $109.77 | 2022 | |
| Electronic Waveform Lab, INC. | $108.79 | 2022-2025 | |
| Allergan, INC. | $83.42 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $58.54 | 2022 | |
| Medtronic, INC. | $56.17 | 2024-2025 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $51.39 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $43.36 | 2022-2023 | Xtampza |
| Bioventus LLC | $40.83 | 2022-2024 | Durolane |
| Janssen Pharmaceuticals, INC | $27.97 | 2021 | |
| Almatica Pharma LLC | $25.26 | 2021 | |
| Pacira Therapeutics, INC. | $24.27 | 2021 | |
| Spr Therapeutics, INC | $24.22 | 2021 | |
| Otto Bock Healthcare LP | $23.81 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.48 | 2025 | Relistor |
| Hartmann USA, INC. | $16.38 | 2024 | Colactive Plus 2x2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.03 | 2021 | |
| Redhill Biopharma INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Mcmurdie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.